Abstract 311P
Background
Chemotherapy is one of the fundamental treatments in cancer patients, which has significantly improved survival rate. Alongside positive effects, many side effects. One of major side effects of these drugs is hepatotoxicity, initially develops as fatty liver and hepatic steatosis, but progresses to liver failure if harmful factor persist. To determine prevalence of fatty liver in breast and gastrointestinal cancers during and after chemotherapy and to investigate some of its effective causes.
Methods
This longitudinal cohort study was performed breast or gastrointestinal cancer patients undergoing chemotherapy at the Oncology Clinic of Birjand University of Medical Sciences, 2016-2017. Before and after chemotherapy, the patients were evaluated by sonography for fatty liver. Data were imported into SPSS software version 19 and analyzed by Chi-Square (or Fisher Test) and McNemar at 5% significance level.
Results
A total of 152 patients were enrolled in the study, of whom 85 had breast cancer and 67 had gastrointestinal cancers. Most patients were in age group of 45-54 years old (48 cases, 31.6%). Mean body mass index (BMI) was 23.17 ± 4.52. Frequency of fatty liver before and after chemotherapy increased from 2% to 46.7% in all patients (p = 0.0001). Frequency of fatty liver after chemotherapy was significantly higher in females than males (34.7 and 52.4%, respectively, p=0.04). There was no significant relationship between chemotherapy induced fatty liver with age (p=0.9), BMI (p=0.17), history of diabetes mellitus (p=0.2), and metabolic syndrome presence (p=0.4). The highest frequency of fatty liver was observed in patients treated with AC-T, FOLFOX and ECF with 53.5%, 42.9% and 29.2%, respectively (p = 0.09).
Conclusions
Results showed that chemotherapy is associated with a significantly increased risk of fatty liver occurrence, which is higher in women than men. However, occurrence of fatty liver following chemotherapy, regardless of diabetes, metabolic syndrome or BMI, as well as age of the patients, can be expected in all scenarios.
Clinical trial identification
Legal entity responsible for the study
Dr. Payam Izadpanahi from Reza Radiotherapy Oncology Center (RROC).
Funding
Birjand University of Medical Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session